WBC alloimmunization: Effects on the laboratory and clinical endpoints of therapeutic granulocyte transfusions

Thomas H. Price, Jeffrey Mccullough, Ronald G. Strauss, Paul Michael Ness, Taye H. Hamza, Ryan W. Harrison, Susan F. Assmann

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Although the subject of many previous studies, the importance of white blood cell (WBC) alloimmunization in granulocyte transfusion therapy has not been settled. In this study, we report the results of the effects of WBC antibodies in the RING (Resolving Infection in Neutropenia with Granulocytes) study, a randomized controlled trial comparing the efficacy of daily granulocyte transfusion therapy plus antimicrobials versus antimicrobials alone; the primary outcome results have been published previously. STUDY DESIGN AND METHODS: One hundred fourteen subjects were enrolled in the study. Serum samples for WBC antibody determination were obtained from each subject at baseline and at 2 and 6 weeks. One hundred subjects had at least one antibody test result. Samples were tested for human leukocyte antigen (HLA) Class I and Class II antibodies as well as for granulocyte-specific antibodies using granulocyte agglutination and immunofluorescence techniques. All testing was performed at a central laboratory. RESULTS: Baseline WBC alloimmunization was modest, depending somewhat on the assay. Seroconversion during the study was slightly higher in the granulocyte transfusion arm, but the differences were not statistically significant. There was no demonstrable effect of the presence of alloimmunization on the primary outcome (survival and microbial response at 42 days), the occurrence of transfusion reactions (either overall or pulmonary), or posttransfusion neutrophil increments. CONCLUSION: The presence or development of WBC antibodies had no demonstrable effect on any clinical aspect of granulocyte transfusion therapy. It appears that, at least in the patient population studied, there is no evidence suggesting need for concern about recipient WBC alloimmunization when prescribing granulocyte transfusions.

Original languageEnglish (US)
JournalTransfusion
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Granulocytes
Leukocytes
Antibodies
Therapeutics
Immunoglobulin Isotypes
Agglutination
HLA Antigens
Neutropenia
Fluorescent Antibody Technique
Neutrophils
Randomized Controlled Trials
Lung
Survival
Infection
Serum
Population

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology

Cite this

Price, T. H., Mccullough, J., Strauss, R. G., Ness, P. M., Hamza, T. H., Harrison, R. W., & Assmann, S. F. (Accepted/In press). WBC alloimmunization: Effects on the laboratory and clinical endpoints of therapeutic granulocyte transfusions. Transfusion. https://doi.org/10.1111/trf.14551

WBC alloimmunization : Effects on the laboratory and clinical endpoints of therapeutic granulocyte transfusions. / Price, Thomas H.; Mccullough, Jeffrey; Strauss, Ronald G.; Ness, Paul Michael; Hamza, Taye H.; Harrison, Ryan W.; Assmann, Susan F.

In: Transfusion, 01.01.2018.

Research output: Contribution to journalArticle

Price, Thomas H. ; Mccullough, Jeffrey ; Strauss, Ronald G. ; Ness, Paul Michael ; Hamza, Taye H. ; Harrison, Ryan W. ; Assmann, Susan F. / WBC alloimmunization : Effects on the laboratory and clinical endpoints of therapeutic granulocyte transfusions. In: Transfusion. 2018.
@article{ac92e04421604add883d60e6cba49b10,
title = "WBC alloimmunization: Effects on the laboratory and clinical endpoints of therapeutic granulocyte transfusions",
abstract = "BACKGROUND: Although the subject of many previous studies, the importance of white blood cell (WBC) alloimmunization in granulocyte transfusion therapy has not been settled. In this study, we report the results of the effects of WBC antibodies in the RING (Resolving Infection in Neutropenia with Granulocytes) study, a randomized controlled trial comparing the efficacy of daily granulocyte transfusion therapy plus antimicrobials versus antimicrobials alone; the primary outcome results have been published previously. STUDY DESIGN AND METHODS: One hundred fourteen subjects were enrolled in the study. Serum samples for WBC antibody determination were obtained from each subject at baseline and at 2 and 6 weeks. One hundred subjects had at least one antibody test result. Samples were tested for human leukocyte antigen (HLA) Class I and Class II antibodies as well as for granulocyte-specific antibodies using granulocyte agglutination and immunofluorescence techniques. All testing was performed at a central laboratory. RESULTS: Baseline WBC alloimmunization was modest, depending somewhat on the assay. Seroconversion during the study was slightly higher in the granulocyte transfusion arm, but the differences were not statistically significant. There was no demonstrable effect of the presence of alloimmunization on the primary outcome (survival and microbial response at 42 days), the occurrence of transfusion reactions (either overall or pulmonary), or posttransfusion neutrophil increments. CONCLUSION: The presence or development of WBC antibodies had no demonstrable effect on any clinical aspect of granulocyte transfusion therapy. It appears that, at least in the patient population studied, there is no evidence suggesting need for concern about recipient WBC alloimmunization when prescribing granulocyte transfusions.",
author = "Price, {Thomas H.} and Jeffrey Mccullough and Strauss, {Ronald G.} and Ness, {Paul Michael} and Hamza, {Taye H.} and Harrison, {Ryan W.} and Assmann, {Susan F.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/trf.14551",
language = "English (US)",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - WBC alloimmunization

T2 - Effects on the laboratory and clinical endpoints of therapeutic granulocyte transfusions

AU - Price, Thomas H.

AU - Mccullough, Jeffrey

AU - Strauss, Ronald G.

AU - Ness, Paul Michael

AU - Hamza, Taye H.

AU - Harrison, Ryan W.

AU - Assmann, Susan F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - BACKGROUND: Although the subject of many previous studies, the importance of white blood cell (WBC) alloimmunization in granulocyte transfusion therapy has not been settled. In this study, we report the results of the effects of WBC antibodies in the RING (Resolving Infection in Neutropenia with Granulocytes) study, a randomized controlled trial comparing the efficacy of daily granulocyte transfusion therapy plus antimicrobials versus antimicrobials alone; the primary outcome results have been published previously. STUDY DESIGN AND METHODS: One hundred fourteen subjects were enrolled in the study. Serum samples for WBC antibody determination were obtained from each subject at baseline and at 2 and 6 weeks. One hundred subjects had at least one antibody test result. Samples were tested for human leukocyte antigen (HLA) Class I and Class II antibodies as well as for granulocyte-specific antibodies using granulocyte agglutination and immunofluorescence techniques. All testing was performed at a central laboratory. RESULTS: Baseline WBC alloimmunization was modest, depending somewhat on the assay. Seroconversion during the study was slightly higher in the granulocyte transfusion arm, but the differences were not statistically significant. There was no demonstrable effect of the presence of alloimmunization on the primary outcome (survival and microbial response at 42 days), the occurrence of transfusion reactions (either overall or pulmonary), or posttransfusion neutrophil increments. CONCLUSION: The presence or development of WBC antibodies had no demonstrable effect on any clinical aspect of granulocyte transfusion therapy. It appears that, at least in the patient population studied, there is no evidence suggesting need for concern about recipient WBC alloimmunization when prescribing granulocyte transfusions.

AB - BACKGROUND: Although the subject of many previous studies, the importance of white blood cell (WBC) alloimmunization in granulocyte transfusion therapy has not been settled. In this study, we report the results of the effects of WBC antibodies in the RING (Resolving Infection in Neutropenia with Granulocytes) study, a randomized controlled trial comparing the efficacy of daily granulocyte transfusion therapy plus antimicrobials versus antimicrobials alone; the primary outcome results have been published previously. STUDY DESIGN AND METHODS: One hundred fourteen subjects were enrolled in the study. Serum samples for WBC antibody determination were obtained from each subject at baseline and at 2 and 6 weeks. One hundred subjects had at least one antibody test result. Samples were tested for human leukocyte antigen (HLA) Class I and Class II antibodies as well as for granulocyte-specific antibodies using granulocyte agglutination and immunofluorescence techniques. All testing was performed at a central laboratory. RESULTS: Baseline WBC alloimmunization was modest, depending somewhat on the assay. Seroconversion during the study was slightly higher in the granulocyte transfusion arm, but the differences were not statistically significant. There was no demonstrable effect of the presence of alloimmunization on the primary outcome (survival and microbial response at 42 days), the occurrence of transfusion reactions (either overall or pulmonary), or posttransfusion neutrophil increments. CONCLUSION: The presence or development of WBC antibodies had no demonstrable effect on any clinical aspect of granulocyte transfusion therapy. It appears that, at least in the patient population studied, there is no evidence suggesting need for concern about recipient WBC alloimmunization when prescribing granulocyte transfusions.

UR - http://www.scopus.com/inward/record.url?scp=85042616470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042616470&partnerID=8YFLogxK

U2 - 10.1111/trf.14551

DO - 10.1111/trf.14551

M3 - Article

C2 - 29498050

AN - SCOPUS:85042616470

JO - Transfusion

JF - Transfusion

SN - 0041-1132

ER -